| AASLD

Home

DYNAMIC EVOLUTION OF CIRCULATING TUMOR DNA IN PATIENTS WITH HEPATOCELLULAR CARCINOMA ACROSS TUMOR STAGES AND TREATMENTS

Read more about DYNAMIC EVOLUTION OF CIRCULATING TUMOR DNA IN PATIENTS WITH HEPATOCELLULAR CARCINOMA ACROSS TUMOR STAGES AND TREATMENTS

<div>Background: Circulating tumor DNA (ctDNA) is a promising non-invasive biomarker in cancer management. We aimed to assess the dynamic evolution of ctDNA in patients with hepatocellular carcinoma (HCC).

HIV COINFECTION INCREASES HBV-INDUCED HEPATIC FIBROGENESIS THROUGH A HIF-1α AND TGF-β1 DEPENDENT PATHWAY

Read more about HIV COINFECTION INCREASES HBV-INDUCED HEPATIC FIBROGENESIS THROUGH A HIF-1α AND TGF-β1 DEPENDENT PATHWAY

<div>Background:

A POSITIVE FEEDBACK BETWEEN CHOLESTEROL SYNTHESIS AND THE PENTOSE PHOSPHATE PATHWAY RATHER THAN GLYCOLYSIS PROMOTES HEPATOCELLULAR CARCINOMA

Read more about A POSITIVE FEEDBACK BETWEEN CHOLESTEROL SYNTHESIS AND THE PENTOSE PHOSPHATE PATHWAY RATHER THAN GLYCOLYSIS PROMOTES HEPATOCELLULAR CARCINOMA

<div>Background: Hepatic cholesterol accumulation and hypercholesterolemia are considered as the risk factors of hepatocellular carcinoma (HCC). However, the therapeutic effects of cholesterol lowering drugs for the treatment of HCC are controversial, indicating that the relationship between cholesterol metabolism and HCC is more complex than anticipated.

TP53BP2 IS ASSOCIATED WITH HBsAg CLEARANCE IN PEGINTERFERON-ALFA-TREATED CHRONIC HEPATITIS B

Read more about TP53BP2 IS ASSOCIATED WITH HBsAg CLEARANCE IN PEGINTERFERON-ALFA-TREATED CHRONIC HEPATITIS B

<div>Background: Hepatitis B surface Antigen (HBsAg) loss occurs in a minor fraction of patients with Chronic Hepatitis B (CHB) under interferon therapy. Identifying the host factors critical for CHB cure can help recognize those who would benefit from interferon therapy.

HEPATOCYTE DELETION OF REGULATORY T CELLS BY ENCLYSIS IS INCREASED IN AUTOIMMUNE HEPATITIS COMPARED TO MASH AND CAN BE TOGGLED BY PPARΑ AGONISTS AND ANTAGONISTS

Read more about HEPATOCYTE DELETION OF REGULATORY T CELLS BY ENCLYSIS IS INCREASED IN AUTOIMMUNE HEPATITIS COMPARED TO MASH AND CAN BE TOGGLED BY PPARΑ AGONISTS AND ANTAGONISTS

<div>Background: The liver is a tolerising organ, to prevent continuous immune activation following the portal influx of antigens from the gut. Regulatory T cells (Treg) dampen inflammation and are important to prevent liver injury. We discovered that hepatocytes engulf and delete live Treg cells by enclysis, which was distinct from known cell-in-cell structure processes and thus can be targeted specifically (PMID: 31693899).

MiR150 DEFICIENCY IN MACROPHAGES IMPROVES ALCOHOL INDUCED HEPATIC STEATOSIS VIA TRANSFERRING THYROID HORMONE RECEPTOR Β ENRICHED EVS TARGETING ADIPOSE TISSUE-LIVER AXIS: THYROID HORMONE RECEPTOR Β, A PROMISING THERAPEUTIC TARGET IN ALD

Read more about MiR150 DEFICIENCY IN MACROPHAGES IMPROVES ALCOHOL INDUCED HEPATIC STEATOSIS VIA TRANSFERRING THYROID HORMONE RECEPTOR Β ENRICHED EVS TARGETING ADIPOSE TISSUE-LIVER AXIS: THYROID HORMONE RECEPTOR Β, A PROMISING THERAPEUTIC TARGET IN ALD

<div>Background: The mechanisms of alcoholic hepatitis (AH) are complex and involve the cross talk between organ systems. MiR150, one of the most abundant microRNAs in immune cells, has been implicated in various liver diseases, but its role in AH pathogenesis remains unclear. We aimed to determine the role of the miR150-mediated immune cells-liver axis in AH pathogenesis.

PREHABILITATION IN LIVER TRANSPLANT CANDIDATES IMPROVES FRAILTY METRICS LEADING TO IMPROVED SURVIVAL

Read more about PREHABILITATION IN LIVER TRANSPLANT CANDIDATES IMPROVES FRAILTY METRICS LEADING TO IMPROVED SURVIVAL

<div>Background: An outpatient prehabilitation strategy is feasible and effective in improving frailty in liver transplant (LT) candidates. We previously showed that attendance to physical therapy (PT) sessions results in a significant reduction in mortality, but were unable identify the frailty change threshold that yields such benefit.

A DEEP LEARNING-BASED HEPATOCELLULAR CARCINOMA STAGING SYSTEM BY MULTI-PHASE COMPUTED TOMOGRAPHY

Read more about A DEEP LEARNING-BASED HEPATOCELLULAR CARCINOMA STAGING SYSTEM BY MULTI-PHASE COMPUTED TOMOGRAPHY

<div>Background:

VALIDATION OF THE R3-AFP MODEL FOR RISK PREDICTION OF HCC RECURRENCE AFTER LIVER TRANSPLANTATION IN THE SILVER CLINICAL TRIAL

Read more about VALIDATION OF THE R3-AFP MODEL FOR RISK PREDICTION OF HCC RECURRENCE AFTER LIVER TRANSPLANTATION IN THE SILVER CLINICAL TRIAL

<div>Background: Hepatocellular carcinoma (HCC) recurrence risk after liver transplantation (LT) has been evaluated with different prediction models following pathology explant analysis. The inclusion of alpha-feto protein (AFP) in these models, such as the novel R3-AFP score (1), have significantly improved risk stratification of HCC recurrence post-LT. The SiLVER trial (NCT00355862) evaluated the efficacy of mTOR inhibitors (Sirolimus-Group B) compared to mTOR-free based immunosuppression (Group A) to reduce post-LT HCC recurrence (2).

ALCOHOL CONSUMPTION ACCELERATES HEPATIC MICROPLASTIC ACCUMULATION VIA IMPAIRED INTESTINAL MUCOSAL BARRIER

Read more about ALCOHOL CONSUMPTION ACCELERATES HEPATIC MICROPLASTIC ACCUMULATION VIA IMPAIRED INTESTINAL MUCOSAL BARRIER

<div>Background: Microplastic (MP) is defined as the plastics size less than <5mm. MP accumulates in humans via ingestion. Therefore, the gut-liver axis may be a important to prevent MP accumulation. However, many of the studies focus on the marine organisms and its biological effect and distribution pattern remain to be elucidated in mammals. Therefore, the present study investigates the role of gut-liver axis in protection of hepatic MP accumulation.

Subscribe to